Genomas delivers Personalized Medicine to modern clinical practices. Genomas develops revolutionary PhyzioType Systems for DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease, and diabetes. These systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance.
Key Features
- Provides DNA-Guided medicine for clinical practices
- Personalizes the prescription of drugs
- Eliminates trial-and-error prescription
- Enables physicians to treat with unprecedented precision
- Avoids significant drug side effects while improving efficacy and enhancing patient compliance
Patients – At A Glance
It seems that nearly everything is being customized today. When we choose a product, we can order just the right size or color or set of options. Medicine is just now catching up. The "one-size-fits-all" approach to prescribing medications is giving way to an advanced, modern method of drug selection based on the capacity of the individual to process (metabolize) the prescription. If you're a patient and would like to learn more, click here.
Refining Patient Prescriptions
PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance.
Predicting Treatment Side Effects
PhyzioType Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a bioclinical algorithm in order to convey to physicians predicted comparisons of side effect risk and efficacy among drugs for the individual patient.
Suite of Solutions
HILOmet PhyzioType™ System
Assisting providers with DNA-based assessment tools to guide their neuro-psychiatric and cardio-metabolic drug choices for patients evidencing treatment resistance or drug intolerance.
More Info
PIMS PhyzioType™ System
Providing physicians with the patient's risk profile for weight- and lipid-related side effects for the major atypical antipsychotics (aaps), olanzapine, quetiapine, and risperidone.
More Info
SINM PhyzioType™ System
Providing physicians with DNA-guided efficacy predictions for aggressive lipid lowering and risk profiles for neuromuscular side effects of atorvastatin, simvastatin, and rosuvastatin.
More Info
GLIM PhyzioType™ System
The GLIM PhyzioType system is currently in development. It will consist of 4 tests predicting blood glucose lowering efficacy (hba1c), weight gain or loss, risk of edema, and likelihood of severe vomiting in response to tzd and incretin medications on a class-wide and drug-specific basis.
More Info